# Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

> **NCT05852730** · PHASE2 · RECRUITING · sponsor: **Repurposed Therapeutics, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Motion Sickness, Space
- Motion Simulation
- Parabolic Flight

## Interventions

- **DRUG:** DPI-386 Nasal Gel
- **DRUG:** Other (e.g., promethazine, meclizine)

## Key facts

- **NCT ID:** NCT05852730
- **Lead sponsor:** Repurposed Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-10
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05852730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05852730, "Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05852730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*